EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton’s Jelly Mesenchymal Stromal Cells

Raquel Cabrera-Pérez iD, Irene Carreras-Sánchez, Ángela Roig-Molina, Alba López-Fernández iD, Irene Portas-Torres iD, Laura Batlle-Morera, Roberto Vélez, Joaquim Vives iD

Cells · 2025

DOI: 10.3390/cells14120862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Raquel Cabrera-Pérez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bioprocessing for Advanced Cell Therapies (BACT) Group, Cell Therapy Service, Blood and Tissue Bank (BST), 08005 Barcelona, Catalonia, Spain. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Tissue Engineering, Wharton Jelly, Mesenchymal Stem Cell Transplantation. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII), Fondo de Investigaciones Sanitarias, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Secondary osteonecrosis (ON) is a common complication in paediatric cancer survivors. Combining multipotent mesenchymal stromal cells (MSCs) with core decompression surgery halts disease progression and stimulates bone regeneration. However, the success of advanced therapy medicinal products (ATMPs) requires versatile “off-the-shelf” tissue engineering products (TEPs). This study evaluated the safety and efficacy of TEPs loaded with allogeneic MSCs from Wharton’s jelly (WJ-MSCs) in a large-animal model of bone regeneration to support a paediatric investigational plan for ON patients. WJ-MSC-laden fibrin-based hydrogels combined with a synthetic bone substitute (PRO-DENSETM) were tested in 16 juvenile sheep (8 males and 8 females) distributed in four experimental groups. Each animal received four cylindrical bone defects in the femoral and tibial epiphyses and was assessed at 6 and 12 weeks. Safety was confirmed, and bone regeneration was observed across all groups. A combination of WJ-MSCs with PRO-DENSETM led to improved histological scores, osteogenesis, and construct integration. Trabecular bone volume also increased more in cellular groups over time. However, effects were inconsistent across groups, reflecting the variability seen in clinical trials and highlighting the significant impact of factors such as immunogenetic compatibility, MSC batch potency, and interaction with the recipient’s microenvironment on the therapeutic effectiveness and successful clinical translation of allogeneic ATMPs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsTissue EngineeringWharton JellyMesenchymal Stem Cell TransplantationBone and BonesAnimalsSheepMaleFemaleBone RegenerationOsteogenesisBone SubstitutesTransplantation, Homologous

Stichwörter der Autor:innen

Wharton’s jellyadvanced therapy medicinal productbone regenerationfibrinmultipotent mesenchymal stromal cellssynthetic bone substitute

Substanzen

Bone Substitutes

Autor:innen und Institutionen

  • Bioprocessing for Advanced Cell Therapies (BACT) Group, Cell Therapy Service, Blood and Tissue Bank (BST), 08005 Barcelona, Catalonia, Spain.
  • Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Catalonia, Spain.
  • Tissue Engineering Unit, Centre for Genomic Regulation (CRG), Barcelona Biomedical Research Park (PRBB), 08003 Barcelona, Catalonia, Spain.
  • Musculoskeletal Tumour Unit and Orthopaedic Surgery Department, Vall d'Hebron University Hospital (HUVH), 08035 Barcelona, Catalonia, Spain.
  • Medicine Department, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Catalonia, Spain.

ORCID-Profile: Raquel Cabrera-Pérez, Alba López-Fernández, Irene Portas-Torres, Joaquim Vives

Förderung

  • Instituto de Salud Carlos III (ISCIII)
  • Fondo de Investigaciones Sanitarias
  • Generalitat de Catalunya
  • ISCIII

Zitieren

APA

Cabrera-Pérez, R., Carreras-Sánchez, I., Roig-Molina, Á., López-Fernández, A., Portas-Torres, I., Batlle-Morera, L., Vélez, R., & Vives, J. (2025). Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton’s Jelly Mesenchymal Stromal Cells. Cells. https://doi.org/10.3390/cells14120862

Vancouver

Cabrera-Pérez R, Carreras-Sánchez I, Roig-Molina Á, López-Fernández A, Portas-Torres I, Batlle-Morera L, et al. Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton’s Jelly Mesenchymal Stromal Cells. Cells. 2025. doi:10.3390/cells14120862

BibTeX
@article{CabreraPrez2025,
  author = {Cabrera-Pérez, Raquel and Carreras-Sánchez, Irene and Roig-Molina, Ángela and López-Fernández, Alba and Portas-Torres, Irene and Batlle-Morera, Laura and Vélez, Roberto and Vives, Joaquim},
  title = {Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton’s Jelly Mesenchymal Stromal Cells},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14120862}
}
Kostenlos starten →